Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 311

Cited In for PubMed (Select 17046465)

1.

Ultra High Performance Liquid Chromatography Method for the Determination of Two Recently FDA Approved TKIs in Human Plasma Using Diode Array Detection.

Fouad M, Helvenstein M, Blankert B.

J Anal Methods Chem. 2015;2015:215128. doi: 10.1155/2015/215128. Epub 2015 May 25.

2.

Gastrointestinal Stromal Tumors (GIST): A Prospective Analysis and an Update on Biomarkers and Current Treatment Concepts.

Koumarianou A, Economopoulou P, Katsaounis P, Laschos K, Arapantoni-Dadioti P, Martikos G, Rogdakis A, Tzanakis N, Boukovinas I.

Biomark Cancer. 2015 May 21;7(Suppl 1):1-7. doi: 10.4137/BIC.S25045. eCollection 2015.

3.

Immune consequences of tyrosine kinase inhibitors that synergize with cancer immunotherapy.

Kwilas AR, Donahue RN, Tsang KY, Hodge JW.

Cancer Cell Microenviron. 2015;2(1). pii: e677.

4.

Therapeutic Efficacy Assessment of CK6, a Monoclonal KIT Antibody, in a Panel of Gastrointestinal Stromal Tumor Xenograft Models.

Van Looy T, Wozniak A, Floris G, Li H, Wellens J, Vanleeuw U, Sciot R, Debiec-Rychter M, Schöffski P.

Transl Oncol. 2015 Apr;8(2):112-8. doi: 10.1016/j.tranon.2015.02.004.

5.

Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges.

Deng GL, Zeng S, Shen H.

World J Hepatol. 2015 Apr 18;7(5):787-98. doi: 10.4254/wjh.v7.i5.787. Review.

6.

Regorafenib treatment for advanced, refractory gastrointestinal stromal tumor: a report of the UK managed access program.

Kollàr A, Maruzzo M, Messiou C, Cartwright E, Miah A, Martin-Liberal J, Thway K, McGrath E, Dunlop A, Khabra K, Seddon B, Dileo P, Linch M, Judson I, Benson C.

Clin Sarcoma Res. 2014 Dec 4;4:17. doi: 10.1186/2045-3329-4-17. eCollection 2014.

7.

Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors.

Cohen NA, Zeng S, Seifert AM, Kim TS, Sorenson EC, Greer JB, Beckman MJ, Santamaria-Barria JA, Crawley MH, Green BL, Rossi F, Besmer P, Antonescu CR, DeMatteo RP.

Cancer Res. 2015 May 15;75(10):2061-70. doi: 10.1158/0008-5472.CAN-14-2564. Epub 2015 Apr 2.

PMID:
25836719
8.

Cardiovascular toxicity of multi-tyrosine kinase inhibitors in advanced solid tumors: a population-based observational study.

Srikanthan A, Ethier JL, Ocana A, Seruga B, Krzyzanowska MK, Amir E.

PLoS One. 2015 Mar 27;10(3):e0122735. doi: 10.1371/journal.pone.0122735. eCollection 2015.

9.

Inhibition of KIT-glycosylation by 2-deoxyglucose abrogates KIT-signaling and combination with ABT-263 synergistically induces apoptosis in gastrointestinal stromal tumor.

Mühlenberg T, Grunewald S, Treckmann J, Podleska L, Schuler M, Fletcher JA, Bauer S.

PLoS One. 2015 Mar 17;10(3):e0120531. doi: 10.1371/journal.pone.0120531. eCollection 2015.

10.

Primary gastrointestinal stromal tumor of the liver treated with sequential therapy.

Lin XK, Zhang Q, Yang WL, Shou CH, Liu XS, Sun JY, Yu JR.

World J Gastroenterol. 2015 Feb 28;21(8):2573-6. doi: 10.3748/wjg.v21.i8.2573.

11.

Retrospective analysis of extra-gastrointestinal stromal tumors.

Yi JH, Park BB, Kang JH, Hwang IG, Shin DB, Sym SJ, Ahn HK, Lee SI, Lim do H, Park KW, Won YW, Lim SH, Park SH.

World J Gastroenterol. 2015 Feb 14;21(6):1845-50. doi: 10.3748/wjg.v21.i6.1845.

12.

Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib.

Reichardt P, Kang YK, Rutkowski P, Schuette J, Rosen LS, Seddon B, Yalcin S, Gelderblom H, Williams CC Jr, Fumagalli E, Biasco G, Hurwitz HI, Kaiser PE, Fly K, Matczak E, Chen L, Lechuga MJ, Demetri GD.

Cancer. 2015 May 1;121(9):1405-13. doi: 10.1002/cncr.29220. Epub 2015 Jan 13.

13.

Somatostatin receptors in gastrointestinal stromal tumors: new prognostic biomarker and potential therapeutic strategy.

Zhao WY, Zhuang C, Xu J, Wang M, Zhang ZZ, Tu L, Wang CJ, Ling TL, Cao H, Zhang ZG.

Am J Transl Res. 2014 Nov 22;6(6):831-40. eCollection 2014.

14.

Advances in the targeted therapy of liposarcoma.

Guan Z, Yu X, Wang H, Wang H, Zhang J, Li G, Cao J, Teng L.

Onco Targets Ther. 2015 Jan 5;8:125-36. doi: 10.2147/OTT.S72722. eCollection 2015. Review.

15.

Combined inhibition of MAP kinase and KIT signaling synergistically destabilizes ETV1 and suppresses GIST tumor growth.

Ran L, Sirota I, Cao Z, Murphy D, Chen Y, Shukla S, Xie Y, Kaufmann MC, Gao D, Zhu S, Rossi F, Wongvipat J, Taguchi T, Tap WD, Mellinghoff IK, Besmer P, Antonescu CR, Chen Y, Chi P.

Cancer Discov. 2015 Mar;5(3):304-15. doi: 10.1158/2159-8290.CD-14-0985. Epub 2015 Jan 8.

PMID:
25572173
16.

Novel receptor tyrosine kinase targeted combination therapies for imatinib-resistant gastrointestinal stromal tumors (GIST).

Mahadevan D, Theiss N, Morales C, Stejskal AE, Cooke LS, Zhu M, Kurtzman D, Swart R, Ong E, Qi W.

Oncotarget. 2015 Feb 10;6(4):1954-66.

17.

Endothelial cell-initiated extravasation of cancer cells visualized in zebrafish.

Kanada M, Zhang J, Yan L, Sakurai T, Terakawa S.

PeerJ. 2014 Dec 23;2:e688. doi: 10.7717/peerj.688. eCollection 2014.

18.

Gastrointestinal stromal tumors with exon 8 c-kit gene mutation might occur at extragastric sites and have metastasis-prone nature.

Ito T, Yamamura M, Hirai T, Ishikawa T, Kanda T, Nakai T, Ohkouchi M, Hashikura Y, Isozaki K, Hirota S.

Int J Clin Exp Pathol. 2014 Oct 15;7(11):8024-31. eCollection 2014.

19.

Indian Council of Medical Research consensus document for the management of gastrointestinal stromal tumors.

Shrikhande SV, Sirohi B, Barreto SG, Chacko RT, Parikh PM, Pautu J, Arya S, Patil P, Chilukuri SC, Ganesh B, Kaur T, Shukla D, Rath GS.

Indian J Med Paediatr Oncol. 2014 Oct;35(4):244-8. doi: 10.4103/0971-5851.144983.

20.

Radiotherapy followed by aurora kinase inhibition targets tumor-propagating cells in human glioblastoma.

Li N, Maly DJ, Chanthery YH, Sirkis DW, Nakamura JL, Berger MS, James CD, Shokat KM, Weiss WA, Persson AI.

Mol Cancer Ther. 2015 Feb;14(2):419-28. doi: 10.1158/1535-7163.MCT-14-0526. Epub 2014 Dec 18.

PMID:
25522764
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk